Trials / Terminated
TerminatedNCT05645744
Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.
A Long-term Follow-up Study in Patients Previously Treated With Mustang Bio, Inc. CAR-T Cell Investigational Products
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 3 (actual)
- Sponsor
- Mustang Bio · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.
Detailed description
Non-interventional, multi-center, long-term follow-up study of subjects previously treated with a Mustang Bio CAR-T cell investigational product in a Mustang Bio sponsored clinical study. Subjects who enroll will be monitored for a total of up to 15 years from the time of their last investigational product infusion.
Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Chronic Lymphocytic Leukemia in Relapse
- Small Lymphocytic Lymphoma, Relapsed
- Waldenstrom's Macroglobulinemia Recurrent
- Follicular B-cell Non-Hodgkin's Lymphoma
- B-cell Lymphoma Refractory
- Mantle Cell Lymphoma Recurrent
- Hairy Cell Leukemia
- Diffuse Large B Cell Lymphoma
- Waldenstrom's Macroglobulinemia Refractory
- Mantle Cell Lymphoma Refractory
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Prior MB-102 CAR-T cell investigational product. | No investigational product will be administered. |
| BIOLOGICAL | Prior MB-106 CAR-T cell investigational product. | No investigational product will be administered. |
Timeline
- Start date
- 2021-09-29
- Primary completion
- 2024-04-12
- Completion
- 2024-04-12
- First posted
- 2022-12-09
- Last updated
- 2024-07-22
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05645744. Inclusion in this directory is not an endorsement.